e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Evolution or revolution in the treatment of asthma and allergies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical, inflammaory and functional analysis before, during and after treatment with Omalizumabe in patients with difficulty control asthma.
M. Ribeiro (SALVADOR/BA, Brazil)
Source:
International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Session:
Evolution or revolution in the treatment of asthma and allergies
Session type:
Thematic Poster
Number:
4022
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Ribeiro (SALVADOR/BA, Brazil). Clinical, inflammaory and functional analysis before, during and after treatment with Omalizumabe in patients with difficulty control asthma.. 4022
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study)
Source: Eur Respir J , 49 (3) 1501885; DOI: 10.1183/13993003.01885-2015
Year: 2017
Managing asthma patients: which outcomes matter?
Source: Eur Respir Rev 2008; 17: 53-61
Year: 2008
Clinical control, quality of life, physical activity levels, and psychosocial factors according to illness perception in subjects with asthma: a cluster analysis
Source: Virtual Congress 2020 – Physical activity and chronic lung disease
Year: 2020
What clinical features underlying GINA step 1-4 drive the level of treatment in patients with asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 57s
Year: 2001
Clinical, functional and laboratory assessment of treatment efficacy in COPD patients
Source: International Congress 2014 – Predictors
Year: 2014
A network analysis of clinical characteristics of patients with COPD: partial results.
Source: International Congress 2018 – Chronic respiratory disease: effects of rehabilitation interventions in patients
Year: 2018
Cluster analysis identifies distinct clinical phenotypes with poor treatment responsiveness in asthma.
Source: International Congress 2018 – Asthma: clinical screening tools
Year: 2018
Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Asthma patients remain poorly controlled despite being prescribed maintenance treatment
Source: Annual Congress 2005 - Allergic rhinitis and asthma in primary care
Year: 2005
Early detection of asthma exacerbations by using action points in self-management plans
Source: Eur Respir J 2013; 41: 53-59
Year: 2013
Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA).
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
"It‘s like living with a time bomb"– European patients‘ perspective on severe asthma symptoms
Source: Annual Congress 2005 - Severe asthma: perception and management
Year: 2005
Relationship between asthma control test (ACT) and clinical, functional and inflammatory markers in treated and non treated asthmatics
Source: Annual Congress 2008 - Inflammatory biomarkers
Year: 2008
Symptom pattern and treatment for people non-compliant with asthma medication
Source: Annual Congress 2005 - Allergic rhinitis and asthma in primary care
Year: 2005
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
Patients with persistent asthma may have poor disease control despite normal lung function: baseline data from a pan-European real-life study
Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Year: 2009
Clinical effect of combined chemotherapy according to guidelines fro the treatment of pulmonary Mtcobacterium complex disease, including a follow-up study.
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
A new observer independent method to assess therapy response in children with severe asthma based on daily lung function
Source: Annual Congress 2013 –Uncontrolled and severe asthma in children
Year: 2013
QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Factors affecting patients’ decision to adjust treatment; secondary analysis of a randomised trial of treatment optimisation in patients with severe asthma
Source: Virtual Congress 2021 – Asthma burden and management I
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept